Protease-mediated arsenic prodrug strategy in cancer and infectious diseases: A hypothesis for targeted activation

Journal of Cellular Physiology

Volumn 214, Issue 3, 2008, Pages 681-686

  Bellacchio, Emanuele ^a   Paggi, Marco G ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; CHELATING AGENT; GELATINASE B; METAL DERIVATIVE; PRODRUG; PROTEINASE; THIOL DERIVATIVE; PEPTIDE; PEPTIDE HYDROLASE; SULFUR;

ARTICLE; CARCINOGENESIS; CELL SURFACE; CHELATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HUMAN; INFECTION; MOLECULAR MODEL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN TARGETING; UPREGULATION; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; COMMUNICABLE DISEASE; METABOLISM; MOLECULAR GENETICS; NEOPLASM;

AMINO ACID SEQUENCE; ARSENIC; COMMUNICABLE DISEASES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDE HYDROLASES; PEPTIDES; PRODRUGS; SULFUR;

EID: 38449113967     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21261     Document Type: Article

References (35)

1. Adams SR, Campbell RE, Gross LA, Martin BR, Walkup GK, Yao Y, Llopis J, Tsien RY. 2002. New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: Synthesis and biological applications. J Am Chem Soc 124:6063-6076.
2. Anderson KC, Boise LH, Louie R, Waxman S. 2002. Arsenic trioxide in multiple myeloma: Rationale and future directions. Cancer J 8:12-25.
3. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. 1997. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 23:406-415.
4. Arthur MJ, Stanley A, Iredale JP, Rafferty JA, Hembry RM, Friedman SL. 1992. Secretion of 72 kDa type IV collagenase/gelatinase by cultured human lipocytes. Analysis of gene expression, protein synthesis and proteinase activity. Biochem J 287:701-707.
5. Bellacchio E. 2005. Complessi chelati di arsenico trivalente attivabili da proteasi e loro uso. Italian Patent and Trademark Office. RM2005A000633. Italy. 16-12-2005.
6. Chintala SK, Zhang X, Austin JS, Fini ME. 2002. Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation. J Biol Chem 277:47461-47468.
7. Cline DJ, Thorpe C, Schneider JP. 2003. Effects of As(III) binding on alpha-helical structure. J Am Chem Soc 125:2923-2929.
8. Cunningham ML, Zvelebil MJ, Fairlamb AH. 1994. Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals. Eur J Biochem 221:285-295.
9. de Mendoza C, Soriano V. 2004. Resistance to HIV protease inhibitors: Mechanisms and clinical consequences. Curr Drug Metab 5:321-328.
10. Deb S, Gottschall PE. 1996. Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 66:1641-1647.
11. Deryugina EI, Quigley JP. 2006. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9-34.
12. Desai PV, Patny A, Gut J, Rosenthal PJ, Tekwani B, Srivastava A, Avery M. 2006. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J Med Chem 49:1576-1584.
13. Dou YM, McHugh T, Lane WV, Rossant CJ, Loring RH. 1994. Interactions of dithiols with p-aminophenyldichloroarsine and nicotinic acetylcholine receptors. J Biol Chem 269:20410-20416.
14. Egeblad M, Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
15. Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E. 2002. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 127:393-398.
16. Fairlamb AH, Smith K, Hunter KJ. 1992. The interaction of arsenical drugs with dihydrolipoamide and dihydrolipoamide dehydrogenase from arsenical resistant and sensitive strains of Trypanosoma brucei brucei. Mol Biochem Parasitol 53:223-231.
17. Farrer BT, McClure CP, Penner-Hahn JE, Pecoraro VL. 2000. Arsenic(III)-cysteine interactions stabilize three-helix bundles in aqueous solution. Inorg Chem 39:5422-5423.
18. Goudreau N, Llinas-Brunet M. 2005. The therapeutic potential of NS3 protease inhibitors in HCV infection. Expert Opin Investig Drugs 14:1129-1144.
19. Hirata K, Tsuji N, Miyamoto K. 2005. Biosynthetic regulation of phytochelatins, heavy metal-binding peptides. J Biosci Bioeng 100:593-599.
20. Kim SC, Singh M, Huang J, Prestigiacomo CJ, Winfree CJ, Solomon RA, Connolly ES Jr. 1997. Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery 41:642-666.
21. Kitareewan S, Roebuck BD, Demidenko E, Sloboda RD, Dmitrovsky E. 2007. Lysosomes and trivalent arsenic treatment in acute promyelocytic leukemia. J Natl Cancer Inst 99:41-52.
22. Kridel SJ, Chen E, Kotra LP, Howard EW, Mobashery S, Smith JW. 2001. Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem 276:20572-20578.
23. Okada Y, Naka K, Kawamura K, Matsumoto T, Nakanishi I, Fujimoto N, Sato H, Seiki M. 1995. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase - gelatinase B) in osteoclasts: Implications for bone resorption. Lab Invest 72:311-322.
24. Ord MG, Stocken LA. 2000. A contribution to chemical defence in World War II. Trends Biochem Sci 25:253-256.
25. Pickering IJ, Prince RC, George MJ, Smith RD, George GN, Salt DE. 2000. Reduction and coordination of arsenic in Indian mustard. Plant Physiol 122:1171-1177.
26. Ram M, Sherer Y, Shoenfeld Y. 2006. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 26:299-307.
27. Rey NA, Howarth OW, Pereira-Maia EC. 2004. Equilibrium characterization of the As(III)-cysteine and the As(III)-glutathione systems in aqueous solution. J Inorg Biochem 98:1151-1159.
28. Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC. 1996. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury. Neurology 46:1626-1632.
29. Shi W, Dong J, Scott RA, Ksenzenko MY, Rosen BP. 1996. The role of arsenic-thiol interactions in metalloregulation of the ars operon. J Biol Chem 271:9291-9297.
30. Sorbi D, French DL, Nuovo GJ, Kew RR, Arbeit LA, Gruber BL. 1996. Elevated levels of 92-kd type IV collagenase (matrix metalloproteinase 9) in giant cell arteritis. Arthritis Rheum 39:1747-1753.
31. Spaltenstein A, Kazmierski WM, Miller JF, Samano V. 2005. Discovery of next generation inhibitors of HIV protease. Curr Top Med Chem 5:1589-1607.
32. Spuches AM, Kruszyna HG, Rich AM, Wilcox DE. 2005. Thermodynamics of the As(III)-thiol interaction: Arsenite and monomethylarsenite complexes with glutathione, dihydrolipoic acid, and other thiol ligands. Inorg Chem 44:2964-2972.
33. Van Valckenborgh E, Mincher D, Di Salvo A, Van R I, Young L, Van Camp B, Vanderkerken K. 2005. Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: A proof of principle in the 5T33MM mouse model. Leukemia 19:1628-1633.
34. Wu YS, Lin WH, Hsu JT, Hsieh HP. 2006. Antiviral drug discovery against SARS-CoV. Curr Med Chem 13:2003-2020.
35. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. 2002. How acute promyelocyte leukaemia revived arsenic. Nat Rev Cancer 2:705-713.